Upper GI biopsies for Adenocarcinoma – how many biopsies should endoscopists take?

Philip Kaye¹*, Daniel Lindsay¹, Srinivasan Madhusudan², Ravinder Vohra³, James Catton³, Craig Platt¹ and Krish Ragunath⁴

¹ Department of Histopathology & Nottingham Digestive Diseases BRC, Nottingham University Hospitals, Nottingham. UK
² Dept of Oncology, University of Nottingham, Nottingham UK
³ Dept of Surgery, Nottingham University Hospitals, Nottingham. UK.
⁴ Dept of gastroenterology, Nottingham Digestive Diseases BRC, Nottingham University Hospitals, Nottingham. UK.

*Corresponding author: philip.kaye@nuh.nhs.uk
   0115 9249924 Ext 66207

Running title: Upper GI biopsy numbers

Word count: 1498

None of the authors have any conflict of Interests to declare
Abstract

Key words: Gastric biopsy, oesophageal biopsy, HER2, Viable tumour, molecular testing

Introduction

HER2 testing is a requirement for a significant proportion of gastro-oesophageal adenocarcinomas as response to Trastumuzab is dependent on positive expression\(^1\). However, expression of HER2 may vary significantly within a tumour and in a gastric resection specimen a threshold of 10% strong positive staining is regarded as positive while in biopsies, a cluster of 5 positive cells showing strong membranous staining is regarded as positive\(^2\) Initial guidelines which were based on no specific evidence recommended “an adequate number of viable biopsy specimens (ideally 6-8) are required"\(^3\). The recently published BSG quality standards in upper gastrointestinal endoscopy\(^4\) have also recommended a minimum of 8 biopsies. Reported concordance between biopsy and resection cases varies quite markedly in the literature between 45-85%\(^5\)-\(^8\). Two studies in particular, both published in 2015, have focussed on how many biopsies are required to ensure maximum correlation between biopsies and the resected specimen. Ahn et al\(^9\) compared 702 paired biopsy and resection cases. They found a high degree of biopsy heterogeneity, but using using ROC analysis concluded that a minimum of 4 biopsies were required to minimise discrepancy. Tominaga et al\(^10\) used a different methodology by examining 84 gastric cancer resection cases and assessing 6 “virtual biopsies” distributed evenly through the luminal compartment of the tumour. They concluded that 5 biopsies would be sufficient for complete correlation with the gastrectomy specimen. Interestingly, they also showed preferential expression in the luminal and lateral aspects of the tumour.

These studies provide vital evidence, but neither have considered the real world scenario where many of the biopsies which are taken do not contain viable tumour. The object of this audit study was to look at the actual number of targeted biopsies taken and determine how many of these fragments actually contain viable tumour (i.e. diagnostic). Our aims was to see if the minimum standard for the recommended number of biopsies is being adhered to, and more importantly, determine the minimum number of biopsies required to get diagnostic material and reach the recommended requirement for HER2 testing.
Methods
This audit was registered with the NUH Trust online Clinical Audit system. 105 consecutive cases of biopsy proven upper GI cancer during 2016 were retrieved using the Winpath laboratory information system. Cases were diagnostic biopsies with a proven diagnosis of upper GI cancer. We therefore did not include cases where the diagnosis of cancer had been missed, or not proven. The cases were then reviewed and the following recorded:

- The total number of endoscopic biopsies taken.
- The total number of endoscopic biopsies containing viable tumour.
- The total number of endoscopic biopsies containing necrotic tumour.
- The anatomical location i.e. oesophageal or gastric.

The total number of biopsies and percentage with viable tumour was calculated, which enabled determination of the number of biopsies required to be taken to establish a diagnosis of cancer. Further, the data was inspected to determine the number of biopsies required to yield 4 or 5 viable tumour fragments. Further, the number of biopsies required for viable tumour fragments was also calculated mathematically.

Results
We assessed 105 diagnostic upper gastrointestinal biopsies. 35 cases (33%) met the minimum national standards of at least 8 biopsies. The relationship between total number of biopsies and viable tumour fragments is shown in table 1. A total of 667 biopsies were taken of which 471 yielded viable tumour. On average, the chance of getting viable tumour with a single biopsy is therefore around 70%, and there is a 30% chance of missing tumour with each biopsy. The chance of missing tumour with multiple biopsies is therefore 0.3^n etc. This translates to a 97% chance of getting at least one viable tumour biopsy with 3 biopsies.

However, for optimal gastric HER 2 testing, evidence suggests that at least 4 or possibly 5 tumour biopsies are required. 70/105 (67%) of cases had at least 4 viable tumour biopsies, but only 47/105 (45%) had 5 or more.

Inspection of our data showed that if only 4 biopsies were taken 7/15 had 4 biopsies with tumour, 7/14 with 5 biopsies, 9/12 with 6 biopsies, 16/17 with 7 biopsies (table 2a). Taking further biopsies beyond 7 did not appear to increase the likelihood of reaching 4 tumour viable biopsies. If however 5 viable tumour biopsies are required, at least 10 biopsies were required for greater than 90% chance of 5 viable biopsies (table 2b). Assuming a fixed probability for a viable tumour biopsy of 0.7 we have constructed a probability tree using the binomial distribution to calculate a 90% chance of getting at least 4 viable tumour biopsies. This amounted to 8 biopsies being required for a 94% chance of obtaining at least four viable tumour biopsies. With
seven biopsies the probability of at least four viable tumour biopsies is less than 90%. This theoretical approach assumes a fixed probability for each biopsy and as a model system could be refined with the collection of more data.

Discussion

Trastuzumab (Herceptin) has become standard of care for first line chemotherapy in patients with metastatic gastro-oesophageal cancer for the small proportion of tumours which strongly express HER2. Most of these patients will have had biopsies only and will not have undergone prior gastrectomy. Recent studies suggest that 4 or 5 viable biopsies are required to reach optimal concordance for HER2 status between biopsy and gastrectomy specimen.

This audit study was undertaken to determine how frequently we met this standard, and how many biopsies were required to be taken to reach this number. BSG guidelines recommend taking 8 tumour biopsies, but no evidence currently exists to support this.

This audit has shown that in our centre which is likely to be representative of the UK in general, only 33% of all endoscopies met the required standard of 8 biopsies. 70% of targeted biopsies contained diagnosable cancer which all things being equal would translate to 3 biopsies being required for a 97% chance of diagnostic success. Few previous studies have looked at this. Choi et al in a prospective study showed very high diagnostic rates when 3-4 biopsies were taken in gastric and colorectal cancer but a previous study in rectal cancer showed less than 80% diagnostic rate in colorectal cancer with 6 biopsies while an even older upper GI study recommended 7 biopsies for a greater than 98% chance of diagnosis.

We are not aware of any studies which have looked at the optimal number of biopsies to be taken to ensure that the target of 4 or 5 viable tumour biopsies are collected for HER2 testing. The evidence here suggests that a minimum of 8 targeted biopsies should yield at least 4 viable tumour biopsies in more than 90% of cases while 5 viable biopsies requires at least 10 biopsies to be taken for a greater than 90% chance of success. Although there is some variation in the literature on the optimal number of viable biopsies needed, the current BSG upper GI quality standards guidelines recommendation of 8 biopsies now has solid evidence to support it. The German guidelines similarly recommend 8 biopsies be taken.

This study was limited by not including cases of intended tumour biopsy which did not yield a positive diagnosis at all and had to be repeated. However, it is likely that the same principle will apply to these cases and that taking at least 8 biopsies will avoid the requirement for repeat endoscopy other than in exceptional cases. It is likely that
the biopsy yield for colorectal cancer will be even lower, as these tumours often have a large residual adenomatous component which may interfere with sampling the invasive component. It would certainly be worth doing a similar study on lower GI cancer.

It is clear that there are multiple factors related to the chance of getting an adequate diagnostic biopsy. These include both tumour characteristics as well as endoscopist skill and experience. This study could not account for these factors, but gives a snapshot of actual practise in our institution where endoscopies are performed by a very wide range of individuals. The evidence presented here suggests that taking at least 8 biopsies will accomplish the task satisfactorily in the vast majority of cases. This study may also be of use to those planning the acquisition of fresh biopsy tissue for research, in particular the 100 000 genome project and other large studies seeking to obtain high quality genetic material. As mentioned, the chance of getting viable tumour with one targeted biopsy is no better than 70% so when harvesting upper GI tumour tissue for this purpose at least two and preferably 3 biopsies should be obtained.

In summary, the results of this audit show that we are currently reaching the national guideline target in only a third of cases, and that only 67% of our cases had sufficient tumour tissue to accurately grade HER2 staining at the 4 viable tumour biopsy threshold (and only 45% at the 5 biopsy mark). Furthermore, we have shown that taking at least 8 biopsies would likely increase our yield of required tissue to over 90%, supporting the national guidance.

**Acknowledgements**

There was no funding for this project

Philip Kaye devised study and wrote the paper

Daniel Lindsay collected data and analysed it

Craig Platt did mathematical calculations and edited paper

Ravider Vohra, James Catton, Srinivasan Madhusudan and Krish Ragunath, edited paper.
1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97. doi:10.1016/s0140-6736(10)61121-x

2. Angela N. Bartley, Mary Kay Washington, Carol Colasacco, et al HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. Journal of Clinical Oncology 35, no. 4 (February 1 2017) 446-464.

3. Ru’schoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637–50.

4. Beg S, Ragunath K, Wyman A et al. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). Gut. 2017 Nov;66(11):1886-1899

5. Yan B, Yau EX, Choo SN, Ong CW, Yong KJ, Pang B, et al. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol. 2011;64(10):880–3.

6. Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006;15(1):65–71.

7. Yang J, Luo H, Li Y, Li J, Cai Z, Su X, et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys. 2012;62(1):221–8. doi:10.1007/s12013-011-9286-1.

8. Yoshida H,Yamamoto N,Taniguchi H et al. Comparison of HER2 status between surgically resected specimens and matched biopsyspecimens of gastric intestinal-type adenocarcinoma. Virchows Arch. 2014 Aug;465(2):145-54

9. Ahn S1, Ahn S, Van Vrancken M et al. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. Oncotarget. 2015 Nov 10;6(35):38372-80

10. Tominaga N, Gotoda T, Hara M et al. Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer. 2016 Apr;19(2):553-60
11. National Institute for Health and Care Excellence. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer. 2010 Nov. https://www.nice.org.uk/guidance/ta208

12. Choi Y, Choi HS, Jeon WK et al. Optimal number of endoscopic biopsies in diagnosis of advanced gastric and colorectal cancer. J Korean Med Sci. 2012 Jan;27(1):36-9

13. Marshall JB, Diaz-Arias AA, Barthel JS, King PD, Butt JH. Prospective evaluation of optimal number of biopsy specimens and brush cytology in the diagnosis of cancer of the colorectum. Am J Gastroenterol. 1993 Sep;88(9):1352-4

14. Graham DY, Schwartz JT, Cain GD, Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology. 1982 Feb;82(2):228-31.

15. Moehler M, Al-Batran SE, Andus T et al. German S3-guideline "Diagnosis and treatment of esophagogastric cancer. Z Gastroenterol. 2011 Apr; 49:461-531.

Tables

Table 1: Relationship between total number of biopsies and viable tumour fragments

| Viable tumour present | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 13 | Total |
|-----------------------|---|---|---|---|---|---|---|---|---|----|-------|
| Total Biopsies        |   |   |   |   |   |   |   |   |   |    | 105   |
| 1                     | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0  | 4     |
| 2                     | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0  | 4     |
| 3                     | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0  | 5     |
| 4                     | 3 | 3 | 2 | 7 | 0 | 0 | 0 | 0 | 0 | 0  | 15    |
| 5                     | 1 | 3 | 3 | 3 | 4 | 0 | 0 | 0 | 0 | 0  | 14    |
| 6                     | 2 | 0 | 1 | 3 | 5 | 1 | 0 | 0 | 0 | 0  | 12    |
| 7                     | 0 | 1 | 0 | 6 | 4 | 1 | 5 | 0 | 0 | 0  | 17    |
| 8                     | 0 | 1 | 0 | 2 | 1 | 0 | 1 | 5 | 0 | 0  | 10    |
| 9                     | 1 | 0 | 0 | 2 | 1 | 3 | 1 | 3 | 2 | 1  | 13    |
| 10                    | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 0  | 4     |
| 11                    | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0  | 3     |
| 12                    | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0  | 3     |
| 13                    | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1  | 1     |
| Total                 | 13| 13| 9 | 23| 16| 8 | 8 | 10| 4 | 1  | 105   |
Table 2 Relationship between number of biopsies and cases with >4 (table 2a) and >5 (table 2b) viable tumour fragments

2a

| Total Number of biopsies | Number of cases | Number with >=4 tumour biopsies |
|--------------------------|-----------------|---------------------------------|
| 4                        | 15              | 7 (47%)                         |
| 5                        | 14              | 7 (50%)                         |
| 6                        | 12              | 9 (75%)                         |
| 7                        | 17              | 16 (94%)                        |
| >=8                      | 32              | 29 (91%)                        |

2b

| Total Number of biopsies | Number of cases | Number with >=5 tumour biopsies |
|--------------------------|-----------------|---------------------------------|
| 5                        | 14              | 4 (29%)                         |
| 6                        | 12              | 6 (50%)                         |
| 7                        | 17              | 10 (59%)                        |
| 8                        | 10              | 7 (70%)                         |
| 9                        | 13              | 10 (77%)                        |
| >9                       | 11              | 10 (91%)                        |

Figure Legend

Figure 1 a: 5 gastric biopsies were taken. Only one (circled) shows cancer. b: Another case with three biopsies taken; one is normal, one is necrotic tumor (blue circle) and only one is viable tumour (red circle) c: high power of viable tumour biopsy d: Her 2 staining on this case is negative (weak staining in benign epithelium) but not sufficient for a conclusive answer